Diamond-Blackfan anemia medical therapy

Jump to navigation Jump to search

Diamond-Blackfan anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Diamond-Blackfan anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diamond-Blackfan anemia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diamond-Blackfan anemia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diamond-Blackfan anemia medical therapy

CDC on Diamond-Blackfan anemia medical therapy

Diamond-Blackfan anemia medical therapy in the news

Blogs on Diamond-Blackfan anemia medical therapy

Directions to Hospitals Treating Diamond-Blackfan anemia

Risk calculators and risk factors for Diamond-Blackfan anemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

  • Corticosteroid therapy
    • Corticosteroids remain the mainstay of treatment after the original report of their efficacy. In a large study of 225 patients, 82% initially responded to this therapy, although many side effects were noted.[1] Some patients remained responsive to steroids, while efficacy waned in others. Individuals with DBA, especially those on corticosteroid treatment, should take reasonable precautions to avoid infections
  • Blood transfusions
    • can also be used to treat severe anemia in DBA. Periods of remission may occur, during which transfusions and steroid treatments are not required.
  • Bone marrow transplantation (BMT)
    • can cure hematological aspects of DBA. This option may be considered when patients become transfusion-dependent because frequent transfusions can lead to iron overloading and organ damage. However, data from a large DBA patient registry indicated that adverse events in transfusion-dependent patients were more frequently caused by BMTs than iron overloading.
  • Cancer treatment
  • Prevention of secondary complications:
      • Iron chelation
      • Deferasirox is recommended in individuals age two years or older.
      • Desferrioxamine
    • Evaluation of Relatives at Risk
      • Molecular genetic testing if the pathogenic variant in the family is known
      • Consideration of other testing (e.g., mean corpuscular volume, eADA, and/or fetal hemoglobin concentration) if the pathogenic variant in the family is not known – especially of relatives being considered as bone marrow donors

References

  1. Vlachos A, Klein GW, Lipton JM (2001). "The Diamond Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond-Blackfan anemia". J. Pediatr. Hematol. Oncol. 23 (6): 377–82. PMID 11563775.